Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Core-shell microcapsules compatible with routine injection enable prime/boost immunization against malaria with a single shot.
Guyon R. et al, (2025), Sci Transl Med, 17
Identification of cross-stage, cross-species malaria CD8+ T cell antigens.
Junqueira C. et al, (2025), Res Sq
A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Dold C. et al, (2025), Science Translational Medicine, 17
Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context.
Diawara H. et al, (2025), BMJ global health, 10
Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study
Hamilton F. et al, (2025), The Lancet Microbe, 6, 100922 - 100922
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Venkatraman N. et al, (2025), The Lancet. Microbe
The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
Datoo MS. et al, (2025), Lancet (London, England), 405, 299 - 301
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.
Stockdale LK. et al, (2025), NPJ vaccines, 10
A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates.
Arunachalam PS. et al, (2024), Sci Transl Med, 16
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.
Hanboonkunupakarn B. et al, (2024), NPJ vaccines, 9
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response
Mentzer AJ. et al, (2024), Nature Medicine, 30, 1384 - 1394
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N. et al, (2024), The Lancet. Infectious diseases, 24, 465 - 475
Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture
Lv X. et al, (2024), iScience, 27
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo MS. et al, (2024), The Lancet, 403, 533 - 544
Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture
Schurz H. et al, (2024), eLife, 13